Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19-IL2 with SABR in Oligometastatic Solid Tumors
NCT02086721Phase 1Completed
- Sponsor
- Maastro Clinic
- Start
- Dec 2015
- Primary completion
- May 2017
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darleukin in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and 2 more, sponsored by Maastro Clinic. Primary endpoint: Toxicity (CTCAE 4.0) at 3 months. Started Dec 2015; status: completed.
02
Drugs
darleukin
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT02086721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086721.